Ashish M. Kamat: IBCG24 has officially concluded

Ashish M. Kamat, Endowed Professor of Urologic Oncology at MD Anderson Cancer Centre, shared on X:

“IBCG24 has officially concluded, and what an inspiring event it was! The passion, dedication, and collaboration on display were truly remarkable. A huge thank you to all the participants, especially our patient advocates, whose valuable insights and unwavering commitment to improving the lives of bladder cancer patients worldwide fuel our mission. We International Bladder Cancer Group are deeply grateful for your partnership!”

Shilpa Gupta retweeted the post, adding the following:

“Thanks Ashish M. Kamat for an amazing International Bladder Cancer Group 2nd #IBCG24 Honored to to co-chair w/ Roger Li, Patrick Hensley.
Loved the discussions from world experts including patient advocates.”

Source: Ashish M. Kamat/X and Shilpa Gupta/X

Ashish M. Kamat is the Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center. He is also President of the International Bladder Cancer Group (IBCG) and International Bladder Cancer Network (IBCN). He is Associate Editor for European Urology Oncology, Editor for the UroToday Bladder Cancer Center of Excellence, directed the MDACC Urologic Oncology Fellowship from 2005-2016, and is an alumnus of the AUA Leadership Program.

Shilpa Gupta is the Director of Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s extensive research focuses on novel drug development and biomarkers of response/resistance in bladder cancer, contributing to numerous published works and leadership roles in clinical trials. Shilpa also got promoted to Professor of Medicine at Cleveland Clinic.